Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Personal Finance
What Holden's exit and huge sale discounts teach us about finance
Share Market News
3 ASX growth shares for your portfolio in 2020
52-Week Highs
Why CSL and these ASX 200 shares are flying high
Share Market News
ALL ORDINARIES finishes higher Wednesday: 8 ASX shares you missed
Share Gainers
Why Cleanaway, Cochlear, Domino's, & Webjet shares are storming higher
⏸️ ASX Shares
There could be more coronavirus ASX pain to come
Share Market News
3 ASX healthcare growth shares to add to your 2020 watchlist
Share Market News
Cochlear share price drops lower after half year results release
Share Market News
5 things to watch on the ASX 200 on Tuesday
Share Market News
Where I'd invest $10,000 in a volatile 2020
Share Market News
3 ASX shares I'm watching this week
Share Market News
4 more ASX shares to watch in week 3 of reporting season
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
